For scientists, moving from an isolated lab role to a cross-functional development team can be a career-defining epiphany. This exposure provides a holistic understanding of the entire drug development process, often sparking the desire to move into broader strategic roles like project management and, eventually, executive leadership.
After a long tenure in big pharma, executives may feel a need to transition to biotech to avoid being typecast. The move allows them to apply their extensive experience in a more agile environment and prove their versatility, preventing career stagnation within a single corporate structure.
Lyora Therapeutics' model is built on acquiring promising, pre-clinically validated programs that larger companies shelved due to strategic shifts. This "asset-driven" approach allows a new company to rapidly build a pipeline without the cost and time of early-stage discovery, capitalizing on the sunk R&D costs of former owners.
Beyond clinical efficacy, patient experience is a key differentiator. Patients strongly prefer single-administration ("one and done") gene therapies over treatments requiring regular injections. This is due to the cumulative stress, cost, and logistical burden of lifelong, recurring treatments, which directly informs therapeutic modality choice.
Despite a challenging environment for the gene therapy sector, the ophthalmology sub-sector is outperforming. Recent large M&A deals and significant venture fundraising rounds signal strong investor confidence in AAV-delivered therapies for eye diseases, bucking the wider market trend and creating a favorable niche for investment.